Compare · CLOV vs NTRA
CLOV vs NTRA
Side-by-side comparison of Clover Health Investments Corp. (CLOV) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLOV and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $56.90B, about 22.4x CLOV ($2.54B).
- Over the past year, CLOV is up 73.8% and NTRA is up 124.1% - NTRA leads by 50.3 points.
- CLOV has been more active in the news (15 items in the past 4 weeks vs 11 for NTRA).
- NTRA has more recent analyst coverage (25 ratings vs 13 for CLOV).
- Company
- Clover Health Investments Corp.
- Natera Inc.
- Price
- $4.68-1.99%
- $404.69+2.46%
- Market cap
- $2.54B
- $56.90B
- 1M return
- +2.97%
- +17.16%
- 1Y return
- +73.84%
- +124.13%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 15
- 11
- Recent ratings
- 13
- 25
Clover Health Investments Corp.
Clover Health Investments, Corp. operates as a Medicare Advantage insurer in the United States. The company through its software platform provides preferred provider organization and health maintenance organization health plans for Medicare-eligible consumers. Clover Health Investments, Corp. was founded in 2014 and is headquartered in Franklin, Tennessee.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest CLOV
- SEC Form 8-K filed by Clover Health Investments Corp.
- Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027
- SEC Form 4 filed by Clover Health Investments Corp.
- Clover Health to Report Third Quarter 2026 Financial Results on November 4, 2026
- SEC Form 4 filed by Clover Health Investments Corp.
- Director Miller Brian James was granted 12,481 shares (SEC Form 4)
- Director Torricelli Robert G was granted 12,481 shares, increasing direct ownership by 7% to 186,897 units (SEC Form 4)
- Chief Executive Officer Toy Andrew sold $1,335,797 worth of shares (318,806 units at $4.19), decreasing direct ownership by 3% to 9,140,510 units (SEC Form 4) to cover taxes
- New insider Torricelli Robert G claimed ownership of 174,416 shares (SEC Form 3)
- SEC Form 3 filed by new insider Miller Brian James
Latest NTRA
- Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
- Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
- SEC Form 4 filed by Natera Inc.
- FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
- Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
- New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
- Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $1,242,645 worth of shares (3,000 units at $414.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 106,914 units (SEC Form 4)
- CEO AND PRESIDENT Chapman Steven Leonard sold $526,144 worth of shares (1,273 units at $413.31) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 96,926 units (SEC Form 4)
- CO-FOUNDER Sheena Jonathan sold $7,008,972 worth of shares (18,064 units at $388.01) as part of a pre-agreed trading plan (SEC Form 4)